Teradyne Reports Third Quarter 2022 Results

On October 7, 2022, the U.S. Department of Commerce published new regulations restricting the export to China of advanced semiconductors, supercomputer technology, equipment for the manufacturing of advanced semiconductors and components and technology for the manufacturing in China of certain semiconductor manufacturing equipment. The new restrictions are lengthy and complex. Teradyne continues to assess the impact of these regulations on its business. At this time, the Company has determined that restrictions on the sale of semiconductor testers in China to test certain advanced semiconductors will impact Teradyne’s sales to certain companies in China. Several multinational companies manufacturing these advanced semiconductors in China have obtained one-year licenses allowing suppliers such as Teradyne to continue to provide testers to the facilities operated by these companies. We expect that other companies manufacturing advanced semiconductors in China will not receive licenses, thereby restricting Teradyne’s ability to provide testers to the facilities operated by these companies that do not receive a license. The Company also is assessing the filing of license requests to sell to and support certain customers in China for certain end uses that, if granted, may reduce the impact of these restrictions on the Company’s business. At this time, Teradyne does not know the impact these end user and end use restrictions will have on its business in China or on future revenues. In addition to the specific restrictions impacting Teradyne’s business, the regulations may have an adverse impact on certain actual or potential customers and on the global semiconductor industry. To the extent the regulations impact actual and potential customers or disrupt the global semiconductor industry, Teradyne’s business and revenues will be adversely impacted.

The Company also has determined that the restrictions on the export of certain US origin components and technology for use in the development and production in China of certain semiconductor manufacturing equipment impact its manufacturing and development operations in China. Teradyne has received a temporary authorization from the Department of Commerce allowing the Company to continue its manufacturing and development operations in China until the Department of Commerce issues a license to replace this temporary authorization. Teradyne will file an application with the Department of Commerce for a license to replace the temporary authorization by November 17, 2022. The Company cannot assess the likelihood or timing of receiving this license. In addition to requesting a license, the Company is implementing procedures for minimizing the impact of these new regulations, but there is no assurance that these procedures will succeed.

Following Russia’s invasion of Ukraine in February 2022, the U.S. and other countries imposed significant sanctions against the Russian government and many Russian companies and individuals. Although Teradyne does not have significant operations in Russia, the sanctions could impact Teradyne’s business in other countries and could have a negative impact on the Company’s supply chain, either of which could adversely affect Teradyne’s business and financial results.

COVID-19 has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne’s workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.

The COVID-19 pandemic has adversely impacted the Company’s results of operations, including increased costs company-wide and constraints within the Company’s supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne’s 2022 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne’s markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne’s ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne’s results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.

Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne’s financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne’s products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company’s largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the Company’s best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed by the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela; sanctions imposed against the Russian government and certain Russian companies and individuals by the U.S., and other countries; the impact of regulations published by the U.S. Department of Commerce relating to semiconductors and semiconductor manufacturing equipment destined for certain end uses in China; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the “Risk Factors” sections of Teradyne’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2022. The forward-looking statements provided by Teradyne in this press release represent management’s views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management’s views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne’s views as of any date subsequent to the date of this release.

TERADYNE, INC. REPORT FOR THIRD FISCAL QUARTER OF 2022          
                     
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
       
                           
          Quarter Ended   Nine Months Ended
          October 2,
2022
  July 3,
2022
  October 3,
2021
  October 2,
2022
  October 3,
2021
                           
Net revenues   $ 827,073     $ 840,766     $ 950,501     $ 2,423,209     $ 2,817,835  
  Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1)     341,694       334,377       379,500       976,508       1,138,227  
                           
Gross profit     485,379       506,389       571,001       1,446,701       1,679,608  
                           
Operating expenses:                    
  Selling and administrative     135,632       139,533       134,829       415,351       404,812  
  Engineering and development     111,715       111,951       107,220       331,781       317,644  
  Acquired intangible assets amortization     4,729       4,871       5,355       14,663       16,293  
  Restructuring and other (2)     1,796       2,044       1,197       19,554       (3,426 )
      Operating expenses     253,872       258,399       248,601       781,349       735,323  
                           
Income from operations     231,507       247,990       322,400       665,352       944,285  
                           
  Interest and other expense (3)     5,310       9,398       24,645       20,204       38,511  
                           
Income before income taxes     226,197       238,592       297,755       645,148       905,774  
  Income tax provision     42,712       40,805       41,037       101,948       115,225  
Net income   $ 183,485     $ 197,787     $ 256,718     $ 543,200     $ 790,549  
                           
Net income per common share:                    
Basic       $ 1.17     $ 1.24     $ 1.56     $ 3.41     $ 4.77  
Diluted       $ 1.10     $ 1.16     $ 1.41     $ 3.17     $ 4.26  
                           
Weighted average common shares - basic     156,364       159,563       164,583       159,325       165,690  
                           
Weighted average common shares - diluted (4)     166,733       171,159       181,987       171,156       185,492  
                           
                           
Cash dividend declared per common share   $ 0.11     $ 0.11     $ 0.10     $ 0.33     $ 0.30  
                           
                           
                           
(1 ) Cost of revenues includes:   Quarter Ended   Nine Months Ended
          October 2,
2022
  July 3,
2022
  October 3,
2021
  October 2,
2022
  October 3,
2021
      Provision for excess and obsolete inventory   $ 12,234     $ 5,105     $ 8,149     $ 18,929     $ 11,775  
      Sale of previously written down inventory     (269 )     (449 )     (824 )     (980 )     (2,043 )
          $ 11,965     $ 4,656     $ 7,325     $ 17,949     $ 9,732  
                           
(2 Restructuring and other consists of:   Quarter Ended   Nine Months Ended
          October 2,
2022
  July 3,
2022
  October 3,
2021
  October 2,
2022
  October 3,
2021
      Employee severance   $ 1,215     $ 383     $ 617     $ 2,148     $ 1,242  
      Litigation settlement     -       -       -       14,700       -  
      Acquisition related expenses and compensation     -       -       275       (201 )     313  
      Contingent consideration fair value adjustment     -       -       -       -       (7,227 )
      Other     581       1,661       305       2,907       2,246  
          $ 1,796     $ 2,044     $ 1,197     $ 19,554     $ (3,426 )
                           
(3 Interest and other includes:   Quarter Ended   Nine Months Ended
          October 2,
2022
  July 3,
2022
  October 3,
2021
  October 2,
2022
  October 3,
2021
      Loss on convertible debt conversions   $ -     $ -     $ 20,153     $ -     $ 25,397  
      Non-cash convertible debt interest     -       -       2,262       -       9,120  
      Pension actuarial gains     -       -       -       -       (627 )
          $ -     $ -     $ 22,415     $ -     $ 33,890  
                           
(4 Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended October 2, 2022, July 3, 2022, and October 3, 2021, 1.5 million, 1.9 million and 6.5 million shares, respectively, have been included in diluted shares. For the nine months ended October 2, 2022 and October 3, 2021, 2.0 million and 8.8 million shares, respectively, have been included in diluted shares. For the quarters ended October 2, 2022, July 3, 2022 and October 3, 2021, diluted shares also included 8.3 million, 9.0 million and 9.8 million shares, respectively, from the convertible note hedge transaction. For the nine months ended October 2, 2022 and October 3, 2021, diluted shares included 9.1 million and 9.8 million shares, respectively, from the convertible note hedge transaction.


CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)                    
                           
          October 2,
2022
  December 31,
2021
           
Assets                        
  Cash and cash equivalents   $ 710,746     $ 1,122,199              
  Marketable securities     65,310       244,231              
  Accounts receivable, net     530,349       550,749              
  Inventories, net     310,754       243,330              
  Prepayments     502,678       406,266              
  Other current assets     7,717       9,452              
      Total current assets     2,127,554       2,576,227              
                           
  Property, plant and equipment, net     415,181       387,240              
  Operating lease right-of-use assets, net     61,430       68,807              
  Marketable securities     111,039       133,858              
  Deferred tax assets     130,207       102,428              
  Retirement plans assets     13,805       15,110              
  Other assets     29,311       24,096              
  Acquired intangible assets, net     55,580       75,635              
  Goodwill     375,799       426,024              
      Total assets   $ 3,319,906     $ 3,809,425              
                           
Liabilities                      
  Accounts payable   $ 167,975     $ 153,133              
  Accrued employees' compensation and withholdings     168,102       253,667              
  Deferred revenue and customer advances     143,591       146,185              
  Other accrued liabilities     126,457       124,187              
  Operating lease liabilities     17,079       19,977              
  Income taxes payable     64,141       88,789              
  Current debt     14,596       19,182              
      Total current liabilities     701,941       805,120              
                           
  Retirement plans liabilities     137,317       151,141              
  Long-term deferred revenue and customer advances     48,488       54,921              
  Long-term other accrued liabilities     15,506       15,497              
  Deferred tax liabilities     1,327       6,327              
  Long-term operating lease liabilities     51,872       56,178              
  Long-term income taxes payable     59,135       67,041              
  Debt       50,195       89,244              
      Total liabilities     1,065,781       1,245,469              
                           
Mezzanine equity     -       1,512              
Shareholders' equity     2,254,125       2,562,444              
      Total liabilities, convertible common shares and shareholders’ equity   $ 3,319,906     $ 3,809,425              
                           
                           
                           
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)                    
                           
          Quarter Ended   Nine Months Ended    
          October 2,
2022
  October 3,
2021
  October 2,
2022
  October 3,
2021
   
Cash flows from operating activities:                    
  Net income   $ 183,485     $ 256,718     $ 543,200     $ 790,549      
                                       
  Adjustments to reconcile net income to net cash provided by operating activities:                    
    Depreciation     23,442       22,018       67,902       67,866      
    Stock-based compensation     12,298       11,418       37,420       34,649      
    Provision for excess and obsolete inventory     12,234       8,149       18,929       11,775      
    Amortization     4,917       8,283       15,012       27,626      
    Losses (gains) on investments     2,463       (100 )     11,436       (4,750 )    
    Deferred taxes     (4,776 )     (9,932 )     (28,373 )     (10,732 )    
    Contingent consideration fair value adjustment     -       -       -       (7,227 )    
    Retirement plans actuarial gains     -       -       -       (627 )    
    Loss on convertible debt conversions     -       20,153       -       25,397      
    Other     218       45       740       243      
                           
    Changes in operating assets and liabilities                  
      Accounts receivable     150,632       269,399       4,248       (103,299 )    
      Inventories     (22,135 )     2,035       (68,817 )     21,943      
      Prepayments and other assets     420       (21,148 )     (94,331 )     (138,564 )    
      Accounts payable and other liabilities     (28,071 )     (21,726 )     (71,682 )     65,064      
      Deferred revenue and customer advances     (20,059 )     (6,490 )     (5,896 )     8,699      
      Retirement plans contributions     (1,279 )     (1,384 )     (3,897 )     (4,123 )    
      Income taxes     (42,185 )     (14,778 )     (31,370 )     (17,406 )    
Net cash provided by operating activities     271,604       522,660       394,521       767,083      
                           
Cash flows from investing activities:                    
  Purchases of property, plant and equipment     (38,929 )     (29,205 )     (128,672 )     (103,162 )    
  Purchases of marketable securities     (19,294 )     (111,384 )     (267,175 )     (509,470 )    
  Proceeds from sales of marketable securities     115,558       93,325       259,200       209,437      
  Proceeds from maturities of marketable securities     42,440       111,064       182,092       571,277      
  Purchase of investment     -       -       -       (12,000 )    
Net cash provided by investing activities     99,775       63,800       45,445       156,082      
                           
Cash flows from financing activities:                    
  Repurchase of common stock     (217,201 )     (209,596 )     (750,000 )     (406,180 )    
  Dividend payments     (17,136 )     (16,440 )     (52,578 )     (49,711 )    
  Payments of convertible debt principal     (9,713 )     (235,169 )     (52,005 )     (301,997 )    
  Payments related to net settlement of employee stock compensation awards     (207 )     (251 )     (32,987 )     (32,045 )    
  Issuance of common stock under stock purchase and stock option plans     12,197       9       28,733       32,590      
Net cash used for financing activities     (232,060 )     (461,447 )     (858,837 )     (757,343 )    
                           
Effects of exchange rate changes on cash and cash equivalents     (596 )     -       7,418       (489 )    
Increase (decrease) in cash and cash equivalents     138,723       125,013       (411,453 )     165,333      
Cash and cash equivalents at beginning of period     572,023       954,441       1,122,199       914,121      
Cash and cash equivalents at end of period   $ 710,746     $ 1,079,454     $ 710,746     $ 1,079,454      
                           




© 2024 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us
ShareCG™ is a trademark of Internet Business Systems, Inc.

Report a Bug Report Abuse Make a Suggestion About Privacy Policy Contact Us User Agreement Advertise